News
Market and company headlines
WSTAll
Loading
11:00-19:00Oct 192 Stories
West Declares Quarterly Dividend
On October 19, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared a fourth-quarter dividend of $0.26 per share on the Company's common stock, an 18% increase over the $0.22 per share paid in the prior quarter. This is the thirty-fourth consecutive annual increase in the Company's dividend. The dividend is payable on November 18, 2026, to shareholders of record on November 11, 2026.
This 146-Old Can Maker Is On a Winning Streak Unseen In Its Half-Century Stock History
Ball Corp stock is on an 11-day winning streak, its longest since NYSE trading began in 1973, while the S&P 500 has slipped. Here is what the data shows.
05:00Oct 191 Story
08:00Oct 151 Story
04:00Oct 141 Story
09:00-11:00Oct 132 Stories
Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms
VEEV's push into early-stage biotech could unlock long-term revenue opportunities as its streamlined software solutions simplify critical drug development processes.
Final Trades: JP Morgan, Meta, West Pharmaceutical Services and the iShares U.S. Energy ETF
The Investment Committee gives you their top stocks to watch for the second half.
08:00Oct 131 Story
06:00Oct 81 Story
20:00-00:00Oct 72 Stories
West Pharmaceutical Services Needs Faster Earnings Growth To Justify Its Price
West Pharmaceutical's sustained premium valuation demands proven earnings and cash flow improvements. See why I rate WST stock a Sell.
West Pharmaceutical Services (WST) Stock Could Be 17% Overvalued As Cash Flow Falls Short
West Pharmaceutical Services has seen its share price climb sharply in recent periods, and that kind of run naturally raises a question for anyone looking at the stock today: Are the cash flows the business can generate over time enough to support where the market is currently pricing West Pharmaceutical Services? The share price has gained 37.2% over the past year, which puts a lot of weight on whether the underlying cash flows can keep backing up that move. The group’s role in supplying...
07:00Oct 71 Story
10:00Sep 291 Story
11:00Sep 281 Story
11:00-14:00Sep 222 Stories
Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.
West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says
West Pharmaceutical Services (WST) could see earnings per share upside of at least 10% to current Wa
02:00Sep 221 Story
03:00Sep 211 Story
10:00-16:00Sep 202 Stories
Layoffs, Cyber Disruptions, Annex 1 Upgrades Might Change The Case For Investing In West (WST)
West Pharmaceutical Services recently announced it will phase out a product line at its Scottsdale facility by the end of September, resulting in 98 layoffs and related manufacturing work being shifted to other Becton, Dickinson and Co. locations. At the same time, the company’s push into higher-value products and Annex 1-related sterility upgrades is being tempered by cyber incident disruptions in its West Vantage segment and tariff- and commodity-driven cost pressures. We’ll now examine...
What Is Drawing Attention To West Pharmaceutical Services (WST)?
West Pharmaceutical Services (WST) is juggling mixed signals after recent updates on its business outlook. Investors now have to balance long-term growth drivers with fresh headwinds from a cyber incident, cost inflation, and a Scottsdale product line shutdown. Recent price action reflects that push and pull. The share price is up 9.89% over the past 90 days and 31.08% year to date, while the 1-year total shareholder return of 42.61% contrasts with a slightly negative 3-year total shareholder...
09:00Sep 182 Stories
Avantor Broadens RIM Single-Use Bioprocessing Reach in APAC
AVTR expands its RIM single-use bioprocessing portfolio across APAC, boosting access to locally made solutions and supporting its bioprocessing growth push.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
11:00-13:00Sep 172 Stories
Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
BBNX's FDA-cleared Mint patch pump expands its diabetes portfolio, with a full U.S. launch planned for the first quarter of 2027.
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
SOLV's strong Q2 performance, growth investments and cost-saving program support its outlook, though higher raw material costs remain a concern.
07:00-12:00Sep 162 Stories
Here's Why You Should Add Avantor Stock to Your Portfolio for Now
AVTR's strong Q2 results, improving orders and raised 2026 outlook support growth prospects, though BMP weakness and uneven demand remain concerns.
Is West Pharmaceutical Services Stock Outperforming the Nasdaq?
West Pharmaceutical Services has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.
07:00Sep 141 Story
06:00Sep 101 Story
12:00Sep 92 Stories
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DVA gains from expanding value-based kidney care, improving dialysis volumes and clinical innovation, though payer-mix and regulatory risks persist.
GE HealthCare Moves StarGuide GX 4D SPECT/CT Toward FDA Clearance
GEHC moves StarGuide GX closer to the U.S. market with an FDA 510(k) submission, advancing its next-generation molecular imaging push.
08:00-11:00Sep 92 Stories
UBS Maintains Buy on West Pharmaceutical Servs, Raises Price Target to $415
UBS analyst Doug Schenkel maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $340 to $415.
The Cooper Companies Gears Up to Post Q3 Earnings: What's in Store?
COO Q3 earnings are likely to benefit from CooperVision strength, improving fertility trends and efficiency gains offsetting Asia-Pacific pressure.
11:00Sep 82 Stories
PACS Expands Florida Footprint With 32-Facility Acquisition
PACS plans to acquire operations of 32 Florida skilled nursing facilities, adding 4,049 licensed beds and establishing a statewide network.
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial
NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.
12:00Sep 72 Stories
Philips Expands Women's Health Ultrasound Portfolio With New Transducer
PHG broadens women's health ultrasound portfolio with the eV14-2v, offering enhanced imaging, a lighter design and remote collaboration.
Novocure Reports Patient Data Exposure in Cybersecurity Incident
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
10:00Sep 44 Stories
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.
Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC
PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.
Cencora Launches Cell and Gene Therapy Enablement for Health Systems
09:00Sep 31 Story
15:00Sep 21 Story
13:00Aug 133 Stories
WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook
WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.
WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story
West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.